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Abstract
Objective—Our goal was to test whether formin homology protein 1 (FHOD1) plays a
significant role in the regulation of SMC differentiation, and if so, whether Rho-kinase (ROCK)-
dependent phosphorylation in the diaphanous auto-inhibitory domain is an important signaling
mechanism that controls FHOD1 activity in SMC.
Methods and Results—FHOD1 is highly expressed in aortic SMCs and in tissues with a
significant SMC component. Exogenous expression of constitutively active FHOD1, but not WT,
strongly activated SMC-specific gene expression in 10T1/2 cells. Treatment of SMC with the
RhoA activator, sphingosine-1-phosphate (S1P), increased FHOD1 phosphorylation at T1141 and
this effect was completely prevented by inhibition of ROCK with Y-27632. Phosphomimetic
mutations to ROCK target residues enhanced FHOD1 activity suggesting that phosphorylation
interferes with FHOD1 auto-inhibition. Importantly, knock-down of FHOD1 in SMC strongly
inhibited S1P-dependent increases in SMC differentiation marker gene expression and actin
polymerization suggesting that FHOD1 plays a major role in RhoA-dependent signaling in SMC.
Conclusions—Our results indicate that FHOD1 is a critical regulator of SMC phenotype and is
regulated by ROCK-dependent phosphorylation. Thus, further studies on the role of FHOD1
during development and the progression of cardiovascular disease will be important.
Introduction
Smooth muscle cell (SMC) differentiation is an important component of vascular
development, and defective control of this process in adult animals has been shown to
contribute to a variety of cardiovascular pathologies, including atherosclerosis and restenosis
(see 1 for review). It is well known that SMC differentiation marker gene expression is
regulated by serum response factor (SRF) binding to conserved CArG cis elements within
the SMC-specific promoters. The myocardin family of SRF co-factors (myocardin and the
Myocardin-Related Transcription Factors, MRTF-A/MKL-1 and MRTF-B/MKL-2) are also
critical and have been shown to be required for SMC differentiation marker gene expression
in a variety of in vitro and in vivo models 2–5. Thus, identifying the signaling mechanisms
by which extrinsic cues regulate SRF/myocardin factor activity will be critical for our
understanding of the control of SMC phenotype.
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Miralles et al. were the first to demonstrate that MRTF-A activity is controlled by the small
GTPase, RhoA and that MRTF-A nuclear localization was enhanced by RhoA-dependent
actin polymerization 6. Studies from our lab and others have shown that regulation of
MRTF-A and MRTF-B by this mechanism plays an important role in the regulation of SMC
phenotype in at least some SMC sub-types 7–9. Of the RhoA effector proteins, Rho-kinase
(ROCK) is the most well-studied and has been shown to enhance actin polymerization
through LIM-kinase mediated inhibition of cofilin and to stimulate contractility by inhibiting
myosin phosphatase. Although the ROCK inhibitor, Y-27632, attenuates SMC-specific
transcription 10,11, it is clear that other RhoA effectors are also involved.
Actin polymerization is also regulated by formin proteins that directly catalyze actin
polymerization through two highly conserved formin homology domains (FH1 and FH2)
that bind profilin and actin, respectively (see 12,13 for reviews). Members of the
diaphanous-related formin (DRF) sub-family (mDia1, mDia2, mDia3, and FHOD1) exist in
an auto-inhibited state maintained by a molecular interaction between the N-terminal
diaphanous inhibitory domain (DID) and the C-terminal diaphanous auto-regulatory domain
(DAD) (see figure 1A). Importantly, the DRFs interact with specific RhoGTPases (Rho,
Rac, Cdc42) through a conserved GTPase-binding domain (GBD) positioned near the DID.
Studies of mDia1 auto-inhibition have demonstrated that RhoA binding to the GBD
interferes with the DID-DAD interaction thus promoting mDia1-mediated actin nucleation
14,15. mDia2 is also activated by RhoA, and we have recently shown that both of these
DRFs are highly expressed in SMC and are critical for RhoA's effects on SMC-specific gene
expression and MRTF nuclear localization 16.
FHOD1 has not been as extensively studied, but based upon several early observations we
assumed it was not a major regulator of SMC differentiation marker gene expression. First,
FHOD1 binds only to Rac, which unlike RhoA, has only minimal effects on SMC-specific
gene expression 10. Second, Rac binding does not activate FHOD1, but serves as a
mechanism for localizing FHOD1 to the plasma membrane 17. Finally, although FHOD1
was shown to be expressed in human SMC and endothelial cell lines 18,19, it was unclear
whether FHOD1 was expressed at appreciable levels in SMC in vivo. Importantly, Takeya et
al. recently demonstrated that FHOD1 was phosphorylated by ROCK at multiple S/T
residues in the DAD domain in endothelial cells and that this phosphorylation interfered
with the DID-DAD interaction 19. These studies were of considerable interest because they
were the first to identify an activation mechanism for FHOD1, and more importantly, they
implicated FHOD1 as an actin nucleating protein downstream of RhoA. Thus, we wanted to
test whether FHOD1 played a significant role in the regulation of SMC differentiation, and
if so, whether ROCK-dependent phosphorylation was an important signaling mechanism
that controlled FHOD1 activity in SMC.
Materials and Methods
Plasmids and Reagents
cDNA encoding human FHOD1 and MRTF-A/B plasmids were a kind gift from Michael
Mendelsohn (Tuffs Medical Center, Boston, MA) and Da-Zhi Wang (Havard, Boston, MA),
respectively. pCMV-Myc-ROCKΔ3 was a generous gift from Keith Burridge (University of
North, Chapel Hill, NC). Full-length and truncation mutations of FHOD1 were generated by
PCR and sub-cloned into the expression plasmid pcDNA3.1 (Clonetech). Aspartate
substitutions at Ser1131, Ser1137, and Thr1141 were generated using the Quikchange Site-
Directed Mutagenesis Kit (Stratagene). The anti-MRTF-A antibody was generated by us and
has been previously described 9. The SM22α Ab was a kind gift from Mario Gimona
(University of Salzburg, Austria), All other Abs were purchased commercially: FHOD1 and
FHOD1 pThr1141 (ECM Biosciences), M2-flag and SM α-actin (Sigma), GAPDH (Santa
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Cruz), SM-MHC (Abbiotec), α-actin, ERK and pERK (Cell Signaling). Y-27632 and
Latrunculin B were purchased from Calbiochem and S1P from Cayman Chemicals.
Cell Culture, Transient Transfections and Reporter Gene Assays
SMCs from mouse thoracic aorta were isolated and cultured as previously described 7. The
maintenance and transfection of multipotential 10T1/2 cells were performed as previously
described 16. In brief, cells were maintained in 48 well plates in 10% serum and were
transfected 24 h after plating at 70–80% confluency using the transfection reagent, TransIT-
LT1 (Mirus), as per protocol. Luciferase assays (Promega) were conducted 24 h following
transfection. The SM22, SM α-actin, and cfos promoters have been previously described
10,20.
siRNA Knockdown
FHOD1 was depleted from primary mouse aortic SMCs using siRNA (Dharmacon) with
following sequences: Sense 5’- GGAAGAGCGGCAGAAGAUUGAGGTT, Anti-sense 5’-
CCUCAAUCUUCUGCCGCUCUUCCTT. Cells were transfected with gene-specific
siRNA (100nM) or non-targeted control (NTC) siRNA designed against GFP using
DharmaFECT reagent 1. After 72 h of knockdown, cells were serum starved for 24 h and
left untreated or treated with S1P (10μM) for an additional 24 h or 12.5 minutes (Erk
phosphorylation).
Western Blots
Samples were obtained from adult C57/Bl6 mice or confluent SMCs and 10T1/2 cell and
lysed in buffer A (50 mM Tris (pH 7.2), 150 mM NaCl, 2 mM EDTA, 1% NP40, 0.5%
Triton X-100) and cleared by centrifugation (4°C for 15 minutes at 14,000 rpm) and protein
concentrations were determined by BCA assay (Pierce). Protein lysates were run on SDS
polyacrylamide gels, transferred to nitrocellulose, and probed with the indicated antibodies.
Immunoflourescence
10T1/2 cells were plated and transfected in 4-well chamber slides, maintained overnight in
media containing 10% serum. Cells were serum-starved for 16 h, fixed in 3.7%
paraformaldehyde/PBS for 20 min, and permeabilized in 0.5% Triton X-100/PBS for 3–4
min. The M2 Flag (1:500), SM α-actin (1:2000), or MRTF-A (1:250) were diluted in 20%
Goat Serum / 3% BSA in PBS and incubated with the fixed cells for 2 hours. Texas Red or
FITC (Jackson ImmunoResearch) conjugated secondary antibodies were used at (1:1000)
while AlexaFluor 555 Phalloidin (Molecular Probes) and DAPI (Molecular Probes) were
used at 1:100 and 1nM, respectively.
Actin sedimentation assays
SMCs transfected with control or FHOD1 siRNA (see above) were subject to actin
sedimentation assays as previously described 21. In brief, cell lysates were centrifuged at
100,000 × g for 1h and the supernatant (G-actin fraction) and pellet (F-actin fraction) were
subjected to Western Blot analysis for α-actin.
Results
FHOD1 is expressed in SMC-containing tissues and stimulates SMC-specific gene
transcription
To begin to address whether FHOD1 was an important regulator of SMC phenotype, we
measured FHOD1 expression in mouse tissues and several cell lines by Western Blot (figure
1B). Although FHOD1 was detected in many tissues, in general, its expression was
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relatively high in many tissues that exhibited strong SMC differentiation marker gene
expression including bladder, lung, stomach, and primary aortic SMCs. To determine
whether FHOD1, like mDia1 and mDia2, could stimulate SMC-specific transcription, we
expressed flag-tagged FHOD1 variants in multi-potential 10T1/2 cells along with several
SMC-specific promoter-luciferase constructs. 10T1/2 cells serve as an excellent model for
studying the signaling pathways that regulate SMC phenotype because we and others have
shown that SMC differentiation marker gene expression can be dramatically up-regulated by
exogenously expressed proteins or by treatment with various agonists such as TGF-β and
sphingosine-1-phosphate (S1P) 7, 22. Figure 1C demonstrates that expression of WT
FHOD1 had no effect on any of the promoters tested reflecting the auto-inhibited nature of
the full-length molecule. However, expression of a constitutively active FHOD1 variant that
lacks the N-terminal auto-inhibitory domain (ΔGBD/DID) strongly stimulated SMC-specific
promoter activity (by 8–25 fold) even though it was expressed at a slightly lower level than
the WT variant. Importantly, constitutively active FHOD1 had no effect on the CArG-
containing c-fos promoter or on the CArG-independent minimal thymidine kinase (TK)
promoter suggesting that this effect was at least somewhat specific.
FHOD1 activity in SMC is regulated by ROCK
Although constitutively active FHOD1 was sufficient to activate SMC-specific transcription,
we were interested in whether FHOD1 activity in our SMC differentiation models was
controlled by ROCK-dependent phosphorylation. To test this, we measured SM22 promoter
activity in 10T1/2 cells co-expressing FHOD1 and constitutively active variants of RhoA
(L63) or ROCK (Δ3). As shown in figure 2A, expression of L63RhoA or ROCKΔ3 by
themselves enhanced SM22 promoter activity around 6 fold and 4 fold, respectively while
expression of FHOD1 had little effect. However, co-expression of FHOD1 with L63RhoA
resulted in a synergistic activation of SM22 promoter activity (to approximately 15 fold)
suggesting that these signaling molecules cooperate to regulate SMC-specific expression.
Importantly, this increase was significantly attenuated by the ROCK inhibitor, Y-27632, and
a similar synergy was observed upon co-expression of ROCKΔ3 with FHOD1. In contrast,
co-expression of FHOD1 with constitutively active Rac (L61) did not lead to synergistic
activation of SMC differentiation marker gene expression, but did result in FHOD1
localization to the plasma membrane and a relatively small increase in cortical actin
polymerization (figure S1).
It has been shown in endothelial cells that FHOD1 was phosphorylated by ROCK at three
highly conserved sites (S1131, S1137, and T1141) just C-terminal to the core DAD domain
and that phosphorylation of these residues activated FHOD1 by interfering with the DID-
DAD interaction 19. To test whether endogenous FHOD1 was phosphorylated by ROCK in
SMC we used a phospho-specific antibody against T1141. As shown in figure 2B, treatment
of cells with S1P, a lipid agonist previously shown to activate RhoA in SMC 7, resulted in a
significant increase in T1141 phosphorylation. Importantly, S1P-dependent and basal T1141
phosphorylation were inhibited by Y-27632 strongly indicating that ROCK phosphorylates
FHOD1 in SMC. To directly test if phosphorylation activates FHOD1 in SMC, we generated
an FHOD1 variant that contained phosphomimetic aspartic acid mutations to all three
residues shown to be phosphorylated by ROCK (3xD). In comparison to WT, the 3xD
variant significantly enhanced FHOD1 activity as measured by actin polymerization (figure
2C), SMC-specific promoter activity (figure 2D), and endogenous SM α-actin expression
(figure 2E). Interestingly, the 3xD variant was not quite as active as the constitutively active
FHOD1 variant lacking the entire DAD domain (ΔDAD).
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FHOD1 activity regulates MRTF nuclear localization
Based upon our previous studies on mDia1 and mDia2, we hypothesized that the effect of
FHOD1 on SMC-specific transcription was mediated by an actin polymerization-dependent
enhancement of MRTF nuclear localization. In support of this idea, the ability of the
FHOD1 3xD variant to stimulate SM22 promoter activity was strongly inhibited by the actin
polymerization inhibitor, latrunculin B (figure 3A) or by co-expression with a dominant
negative MRTF (figure 3B). Furthermore, the 3xD variant synergistically enhanced
transactivation of the SM22 promoter by MRTF-B, an effect not observed with WT FHOD1
(figure 3C). In excellent agreement with these findings, endogenous MRTF-A (figure 3D)
and GFP-MRTF-B (figure 3E) localized to the nucleus in 100% of cells expressing the
phosphomimetic FHOD1 variant while cells expressing Wt FHOD1 exhibited little MRTF
nuclear localization (16 +/− 5% for MRTF-A, p<0.05; and 3 +/− 2 % for GFP-MRTF-B,
p<0.05).
FHOD1 is required for S1P-dependent SMC differentiation
Since we have previously shown that S1P up-regulates SMC differentiation marker gene
expression through a RhoA-dependent increase in actin polymerization 7, we wanted to
determine whether endogenous FHOD1 was required for this response. We used standard
siRNA methods to knock-down FHOD1 expression in SMCs, and as shown in figure 4b, we
consistently achieved about a 60–70% reduction in FHOD1 protein when compared to cells
transfected with nontargeted control siRNA. Treatment of serum-starved SMC with S1P
resulted in a significant increase in endogenous SM MHC, SM22, and SM α-actin
expression in control cells, and importantly this increase was significantly attenuated in the
FHOD1 knock-down SMC (figure 4a). Knockdown of FHOD1 had no effect on GAPDH
expression, tubulin expression (data not shown) or on S1P-dependent activation of ERK
(figure 4c), indicating that depletion of FHOD1 did not have significant negative effects on
normal cell function or other S1P-dependent signaling pathways.
We also measured changes in actin polymerization in this model. As shown in figure 5,
treatment of control SMCs with S1P increased stress fiber formation as measured by
phalloidin staining and significantly increased the ratio of F-actin to G-actin as measured by
actin sedimentation assays. Importantly, knock-down of FHOD1 significantly attenuated
these S1P-induced changes. These results are in excellent agreement with the down
regulation of SMC differentiation marker gene expression observed in FHOD1 depleted
SMC and strongly suggest that FHOD1 plays a critical role in the RhoA-dependent
regulation of SMC phenotype.
Discussion
Extensive evidence indicates that RhoA activity stimulates SMC differentiation marker gene
expression by promoting MRTF activity (reviewed in 23). This effect is mediated by
increased actin polymerization and we have previously demonstrated that the RhoA
effectors, mDia1 and mDia2, were involved in this response. We now demonstrate that an
additional member of the mDia family, FHOD1, is also highly expressed in SMC and
regulates RhoA-dependent stimulation of actin polymerization and SMC differentiation
marker gene expression. Interestingly, FHOD1 activity in SMC is not directly regulated by
an interaction with RhoA. Instead, our data indicate that FHOD1 is regulated by ROCK-
dependent phosphorylation.
It is clear that disruption of the auto-inhibitory DID-DAD interaction is required for DRF
activation. Crystal structure studies have revealed that the highly conserved amphipathic
core DAD sequence, MDSLLEAL, binds tightly to a hydrophobic pocket on the DID
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surface15. In addition, a highly conserved basic domain just C-terminal to the core DAD
contributes to the DID-DAD interaction strongly suggesting that electrostatic forces are also
important 24. Although GTPase binding is critical for the activation of most DRFs, it is
becoming clear that other mechanisms are also involved (see 12 for review). Our results
indicate that FHOD1 is phosphorylated by ROCK in SMC and provide further support for
the idea that phosphorylation disrupts the DID-DAD interaction to activate FHOD1 19.
Interestingly, the 3xD phosphomimetic did not stimulate SMC-specific transcription as
strongly as the constitutively active ΔDAD variant, perhaps suggesting that other factors are
required for full FHOD1 activation in SMC. Providing additional support for this alternative
activation mechanism, we have recently demonstrated that mDia2 activity is also enhanced
by ROCK-dependent phosphorylation of two conserved S/T residues just C-terminal to the
DAD basic domain (Staus and Mack, unpublished observations). Whether mDia1 or mDia3
are regulated by phosphorylation has not been examined, but this mechanism could provide
specificity to DRF activation and additional spatial and/or temporal control over FHOD1
and mDia2 activity.
Because RhoA activates a number of downstream effectors that regulate actin
polymerization and cytoskeletal remodeling, it has been somewhat difficult to determine the
precise contributions of each to the control of SMC differentiation marker gene expression.
The negative effects of Y-27632 on SMC differentiation marker gene expression have been
attributed mainly to attenuation of LIM kinase/cofilin signaling. 7,25–27. However, in light
of the current results, decreased FHOD1 and mDia2 activity must also be taken into account.
Our demonstration of relatively high FHOD1 expression in SMC when coupled with the
results of our gain/loss of function experiments indicate that FHOD1 plays a significant role
in regulating SMC phenotype. Interestingly, individual knock-downs of mDia1 or mDia2
also decreased SMC-specific gene expression in this model (data not shown) suggesting that
each of these DRFs has a non-redundant function required for full MRTF activation, or
alternatively, that these proteins interact functionally or physically to regulate actin
polymerization. In support of the latter, we have recently demonstrated that endogenous
mDia2 and FHOD1 could be co-immunoprecipitated from SMC lysates (Staus and Mack,
unpublished observations). Interestingly, we have not yet observed statistically significant
changes in endogenous MRTF-A nuclear localization in FHOD1 knockdown SMC upon
S1P-treatment (at least at early time-points), and it is possible that FHOD1 knockdown
inhibits SMC-specific gene expression by other mechanisms downstream of MRTF nuclear
localization, perhaps at the level of transcription complex formation. Clearly, additional
experiments will be required to determine the precise importance of each of the RhoA-
dependent DRFs and whether they have specific functions in regulating SMC
differentiation.
Activation of FHOD1 by DAD phosphorylation may present a unique mechanism by which
different signaling pathways can converge to regulate SMC phenotype. For example, cGMP-
dependent protein kinase (PKG) has been shown to promote the contractile SMC phenotype
in vitro and in vivo but the mechanism by which this occurs is not well understood 28,29.
Interestingly PKG has also been shown to phosphorylate the FHOD1 DAD at Ser-1131 18,
and it is intriguing to postulate that phosphorylation-dependent activation of FHOD1 may
explain the effects of PKG on SMC marker gene expression.
In summary, our results indicate that FHOD1 plays a critical role in RhoA-dependent
regulation of SMC-specific gene expression and that ROCK-dependent phosphorylation
regulates FHOD1 activity in SMC (Figure 6). The importance of FHOD1 in SMC
differentiation during vascular development and in the progression of cardiovascular disease
will be critical areas for future investigation.
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Figure 1. FHOD1 is expressed in SMC-containing tissues and stimulated SMC-specific gene
transcription
A) Molecular regulation of FHOD1. ROCK-dependent phosphorylation of three conserved
residues within the DAD domain activates FHOD1 while binding to Rac regulates FHOD1
subcellular localization. B) Western Blot of FHOD1, SM α-actin, SM22, and GAPDH
expression in the indicated cell-lines and tissues from adult C57/Bl6 mice. C) Flag-tagged
wild-type (WT) or ΔGBD/DID FHOD1 variants were transfected into 10T1/2 cells along
with luciferase reporter constructs driven by the indicated promoter. Luciferase activity or
was analyzed at 24h and is expressed relative to plus empty expression vector (EV). Protein
expression (inset), * p<0.05 versus plus empty vector.
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Figure 2. ROCK-dependent phosphorylation of FHOD1 activated SMC-specific gene expression
A) SM22 luciferase and constitutively active RhoA (L63) or ROCK (Δ3) were transfected
into 10T1/2 cells plus/minus flag-FHOD1. In some experiments cells were treated with
Y-27632 (Y) for 8h prior to luciferase determination. * p<0.05 versus minus FHOD1, **
p<0.05 versus L63 RhoA + FHOD1. B) Primary mouse SMCs were serum starved for 24h
and then pre-treated with increasing amounts of Y-27632 (10, 25, 50, 100μM) for 90 m and
the phosphatase inhibitor, calyculin A (50nM), for 5 m. After addition of S1P (10μM),
FHOD1 phosphorylation was measured at 7.5 m using a phospho-specific antibody against
Thr-1141. C and E) 10T1/2 cells were transfected with WT FHOD1 or an FHOD1 variant
containing phosphomimetic mutations to the three ROCK target residues within the auto-
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inhibitory domain (3xD). Cells were serum starved in 0.5% FBS containing media for 24h,
and then stained for actin polymerization (C) or endogenous SM α-actin expression (E). D)
The indicated flag-FHOD1 variants and luciferase reporters were transfected into 10T1/2
cells and luciferase activity was measured at 24h. * p<0.05 versus Wt. ** p<0.05 versus
3xD.
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Figure 3. FHOD1 regulated MRTF sub-cellular localization and activity
A) 10T1/2 cells were transfected with the 3xD FHOD1 variant and SM22 luciferase. Some
cells were treated with 10μM latrunculin B (LB) for 6h prior to luciferase determination. *
p<0.05 versus untreated. B) The 3xD FHOD1 variant was co-transfected with dominant
negative MRTF and SM22 luciferase. * p<0.05 versus FHOD1 plus EV. C) SM22
luciferase, MRTF-B, and either WT or 3xD FHOD1 were co-transfected into 10T1/2 cells. *
p<0.05 versus Wt FHOD1 plus MRTF-B. D and E) Localization of endogenous MRTF-A
(D) or GFP-MRTF-B (E) in serum starved 10T1/2 cells co-expressing Wt or 3xD FHOD1.
Staus et al. Page 12













Figure 4. Knock-down of FHOD1 in SMC inhibited SMC differentiation marker gene expression
A) Primary aortic SMC were transfected with non-targeted control (NTC) or FHOD1
siRNAs for 72h. Following 24h of complete serum starvation, cells were treated with S1P
for an additional 24h. Lysates were subjected to Western Blot analysis using the indicated
antibody. B) Quantification of FHOD1 and SM marker gene expression from five
independent experiments. Protein expression was normalized to GAPDH expression and is
expressed relative to NTC cells treated with S1P set to 1. * p<0.05. C) Control and FHOD1
knockdown SMC were treated with S1P for 12.5 minutes. ERK activity was then measured
by Western Blotting using a phospho-specific ERK antibody.
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Figure 5. Knock-down of FHOD1 inhibited S1P-dependent actin polymerization
SMCs were plated on 10μg/mL fibronectin, depleted of FHOD1 by siRNA for 72h, serum
starved for 24h, and treated with S1P for 30 min. Actin polymerization was measured by
phalloidin staining (top panels) and actin sedimentation assays (middle panels; see methods
for more details). The results of three separate actin sedimentation experiments are
quantified in the bottom panel. * p<0.05 versus untreated NTC; ** p<0.05 versus S1P-
treated NTC.
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Figure 6. The RhoA-dependent signaling pathways that regulate SMC differentiation
RhoA activates mDia1, mDia2, and ROCK through direct binding. ROCK activity
stimulates actin polymerization through LIM-kinase-mediated inhibition of cofilin. Our
recent results (shaded box) suggest that ROCK also enhances the activities of FHOD1 and
mDia2 through direct phosphorylation of the DAD auto-regulatory domains of these
proteins. Collectively these pathways reduce cellular G-actin pools leading to MRTF nuclear
accumulation, and our data suggest that all three DRFs are required for full RhoA-dependent
activation of SMC-specific gene expression.
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